The findings showed that, in comparison to normal tissues, NOTCH3 expression was lower in sarcoma, esophageal, head and neck, kidney, leukemia, liver, lung, pancreatic, and colorectal cancers but higher in bladder, colorectal, gastric, head and neck, kidney, and leukemia cancers (Fig. 2A).Remarkably, some data also showed that NOTCH3 was downregulated in sarcoma, renal, ovarian, esophageal, and head and neck cancers. This evidence concerns the gene NOTCH3 and head and neck cancer.